Sur180 Therapeutics aims to use the hypothalamic pituitary adrenal axis, commonly known as the stress system, and the abundant presence of corticotrophin-releasing hormone (CRH) and its receptors (CRHR) as a therapeutic target against endometriosis. Our solution departs from the predominantly conventional focus on the gonadal axis towards a therapeutic focus on the stress axis.

 

We take advantage of safe, out-of-patent, but never commercialized small molecules that antagonize the CRHR type 1 (CRHR1). Our data indicates that inhibiting CRHR1 using an orally available pill could desensitize central pain mechanisms1 and stop lesion growth, thus delivering sustained symptom relief to endometriosis patients. Repositioning a molecule known to be safe will significantly decrease developmental costs, which could be translated into savings for health insurances and patients, increasing the commercial attractiveness of our novel product.